https://www.selleckchem.com/products/au-15330.html
16; 95% confidence interval [CI] 1.02-1.32; P = 0.019), and composite remission (OR 2.32; 95% CI 1.55-3.49; P 0.001). Higher week 14 infliximab concentrations were also independently associated with week 54 composite remission (OR 2.05; 95% CI 1.10-3.82; P = 0.023). Based on receiver operating characteristic curve analysis, week 14 infliximab concentrations thresholds with combined maximal sensitivity and specificity of ≥20.2 μg/mL at week 2, ≥15 μg/mL at week 6, and ≥7.2 μg/mL at week 14 were associated with week 14 composite rem
Like
Comment
Share
